Last Update 26 Jun 26
Fair value Increased 38%GRDN: Higher P/E Expectations Will Support Bullish Repricing Thesis
Guardian Pharmacy Services' updated analyst price target has moved from $34 to $47, with analysts pointing to adjusted discount rate assumptions, refined revenue growth and profit margin forecasts, and a higher future P/E estimate as key drivers of the change.
Analyst Commentary
Recent research on Guardian Pharmacy Services points to growing interest in the stock’s valuation framework, with multiple firms updating their views within a short time frame. While the published Street Research mainly highlights upbeat commentary, it still gives useful clues on what analysts are watching most closely around execution, growth assumptions, and P/E expectations.
Bullish Takeaways
- Bullish analysts are reinforcing constructive views on Guardian Pharmacy Services by raising published price targets. This supports the idea that the updated P/E assumptions and discount rates used in their models are being treated as reasonable within current coverage.
- Recent initiations with a positive stance indicate that Guardian Pharmacy Services is gaining traction on research desks. This is often a sign that analysts see enough potential growth drivers and margin opportunities to justify new coverage.
- The repeated focus on “here’s why” in recent reports suggests analysts are actively stress testing revenue and profit forecasts. This can help keep valuation work grounded in detailed operating assumptions rather than simple multiple expansion.
- Multiple bullish updates within a tight time window may signal growing confidence that Guardian Pharmacy Services can execute against the revenue mix and cost structure that analysts are using in their models.
Bearish Takeaways
- Even within supportive research, the emphasis on refined discount rate and P/E inputs points to sensitivity around valuation. Any shift in rates, sector sentiment, or earnings visibility could pressure these targets.
- The need to adjust revenue growth and margin forecasts suggests that analyst models for Guardian Pharmacy Services are still evolving. This leaves room for disappointment if actual results do not line up with current assumptions.
- Positive initiations and target increases can raise investor expectations around execution. This may leave limited room for missteps on profitability, working capital, or capital allocation before sentiment cools.
- Because the detailed research text is not fully disclosed, investors should be cautious about relying solely on headline target moves without understanding the underlying scenarios, especially around long term growth and terminal P/E assumptions.
What’s in the News for Guardian Pharmacy Services
- Guardian Pharmacy Services announced leadership transitions effective July 1, 2026, with Executive Vice President Kendall Forbes retiring and David Morris moving from Executive Vice President and Chief Financial Officer to Chief Operating Officer. Source: Guardian Pharmacy Services, Inc. Announces Leadership Transitions
- In connection with these changes, Will Mudd, currently Senior Vice President, Finance, has been appointed Chief Financial Officer effective July 1, 2026, after overseeing financial accounting, reporting, revenue cycle management, and total rewards since 2012. Source: Guardian Pharmacy Services, Inc. Announces Leadership Transitions
- Truist Securities raised its price target on Guardian Pharmacy Services while maintaining a Buy rating, citing growth opportunities through organic expansion and acquisitions, as well as the company’s technology capabilities and financial flexibility. Source: Truist raises Guardian Pharmacy stock price target on growth outlook
- Guardian Pharmacy Services reported that from March 18, 2026 to March 31, 2026, it repurchased 1,020,000 shares for US$30.28m, completing the buyback tranche announced on March 23, 2026. Source: Company key developments
- The company confirmed full year 2026 revenue guidance in the range of US$1.40b to US$1.42b, in line with its previous guidance range. Source: Company key developments
Valuation Changes for Guardian Pharmacy Services
- Fair Value: The updated analyst fair value has moved from $34 to $47, a rise of about 38%, reflecting a higher modeled valuation for Guardian Pharmacy Services.
- Discount Rate: The discount rate has risen slightly from 6.96% to 7.11%, indicating a modestly higher required return being used in analyst models.
- Revenue Growth: The revenue growth assumption has fallen from 5.83% to 4.18%, signaling a more conservative outlook on top line expansion for Guardian Pharmacy Services.
- Net Profit Margin: The profit margin estimate has risen from 5.25% to 5.54%, a small uplift that points to slightly stronger expected profitability in future modeling.
- Future P/E: The future P/E multiple has increased from 30.50x to 39.86x, implying that a larger share of the updated fair value reflects higher valuation multiples rather than revenue growth alone.
Catalysts
About Guardian Pharmacy Services
Guardian Pharmacy Services operates a national network of long term care pharmacies focused on assisted living and other senior care settings.
What are the underlying business or industry changes driving this perspective?
- Growing senior and high acuity populations in assisted living facilities should support sustained mid to high single digit organic resident growth and increasingly complex drug regimens, expanding revenue per resident and total revenue.
- Rising consolidation among assisted living facility operators is likely to favor scaled, specialized providers, allowing Guardian to deepen national partnerships, win multi-state contracts and improve route density, which should support higher margins and earnings.
- Continued maturation of the 2 to 5 year pharmacy cohorts and optimization of recently acquired and greenfield locations are expected to lift location level profitability, narrowing the current 80 basis point margin drag and enhancing adjusted EBITDA margin and earnings growth.
- Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density and national scale, driving incremental revenue and operating leverage.
- Ongoing negotiations with payers, potential evolution toward more value based arrangements and demonstrated ability to offset policy headwinds such as those tied to the Inflation Reduction Act should stabilize reimbursement, protect net margins and support durable EPS growth.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Guardian Pharmacy Services's revenue will grow by 4.2% annually over the next 3 years.
- Analysts assume that profit margins will increase from 3.6% today to 5.5% in 3 years time.
- Analysts expect earnings to reach $91.3 million (and earnings per share of $1.26) by about June 2029, up from $53.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $107.2 million in earnings, and the most bearish expecting $77.0 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 40.1x on those 2029 earnings, down from 46.4x today. This future PE is greater than the current PE for the US Healthcare industry at 23.6x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Policy and reimbursement changes tied to Medicare Part D and the Inflation Reduction Act could prove more disruptive than anticipated if negotiations with PBMs and payers fail to fully offset headwinds over time. This would pressure revenue growth and adjusted EBITDA margins and ultimately limit earnings expansion.
- Given management expects reported revenue growth to be relatively flat in 2026 despite powerful demographic tailwinds, any prolonged slowdown in assisted living resident admissions or seasonal reluctance to move loved ones into facilities could weaken the pace of organic resident growth. This would dampen revenue and constrain operating leverage.
- The strategy depends heavily on integrating a robust pipeline of acquisitions and greenfield startups. If newly acquired or contiguous locations take longer than the expected four years to reach mature profitability, the current 80 basis point drag from recent investments could increase and structurally cap EBITDA margins and earnings growth.
- Industry consolidation among assisted living facility operators and shifts toward value based models may increase bargaining power for large payers and customers. If Guardian is forced into less favorable contract terms or higher performance risk without commensurate upside, this could compress net margins and create volatility in earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $47.0 for Guardian Pharmacy Services based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $91.3 million, and it would be trading on a PE ratio of 40.1x, assuming you use a discount rate of 7.1%.
- Given the current share price of $38.88, the analyst price target of $47.0 is 17.3% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Guardian Pharmacy Services?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.